---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-028529"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:39:38.865719+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nasdaq panel grants Brainstorm Cell Therapeutics extension to June 30, 2025 to regain listing compliance

## Summary
- Nasdaq Hearings Panel granted extension to June 30, 2025 to regain compliance with $35M minimum Market Value of Listed Securities.
- Company plans to meet $2.5M minimum stockholders' equity requirement as alternative to MVLS compliance.
- Extension conditioned on demonstrating compliance with Nasdaq Listing Rule 5550 and progress in capital raising.
- Company cannot assure success in raising capital or satisfying equity requirement by the extension date.
- Plan presented at February 25, 2025 hearing; capital raising activities are a key component.

## SEC filing metadata
- accession: 0001104659-25-028529
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465925028529/0001104659-25-028529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465925028529/tm2510584d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-028529
- JSON: https://secwatch.observer/filing/0001104659-25-028529.json
- Plain text: https://secwatch.observer/filing/0001104659-25-028529.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.